27 commercial payer policies list J2508. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
27 policies from 15 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J2508 |
|---|---|---|
| Elfabrio (pegunigalsidase alfa intravenous infusion)Effective 07/01/2024 - 06/30/2025 | Jul 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Elfabrio (pegunigalsidase alfa) | Not recorded | Prior auth requiredInferred from policy title |
| Elfabrio (pegunigalsidase alfa)Effective 07/01/2025 - 06/30/2026 | Jul 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Elfabrio (pegunigalsidase)Effective 10/01/2023 - 06/30/2024 | Oct 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2508 |
|---|---|---|
| Agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Fabry disease enzyme replacement therapy: agalsidase agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio) – Minnesota Health Care Programs | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Fabry disease enzyme replacement therapy: agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Enzyme Replacement Therapy (ERT) for Fabry Disease: Agalsidase Beta (e.g., Fabrazyme) and Pegunigalsidase alfa (e.g., Elfabrio) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Pegunigalsidase Alfa-iwxj (Elfabrio) | Aug 1, 2023 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Pegunigalsidase alfa-iwxj (Elfabrio); CP.PHAR.512 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Elfabrio (pegunigalsidase alfa-iwxj) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2508 |
|---|---|---|
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |